Goodwill and Intangible Assets, Net Narrative (Details) $ in Millions	3 Months Ended		12 Months Ended
	Jun. 30, 2020 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2020 USD ($) item	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Goodwill and Intangible Assets [Line Items]
Amortization expense associated with definite-lived intangible assets				$ 44	$ 40	$ 47
Impairment of goodwill			$ 3
2021			63
2022			60
2023			60
2024			59
2025			57
Thereafter			278
Net Carrying Value			577	$ 369
WPH
Goodwill and Intangible Assets [Line Items]
Impairment of goodwill	$ 3
Automotive Segment
Goodwill and Intangible Assets [Line Items]
Impairment of goodwill		$ 87
Home Fashion Segment
Goodwill and Intangible Assets [Line Items]
Impairment of goodwill			3
Pharma Segment
Goodwill and Intangible Assets [Line Items]
Business combination, definite-lived intangible assets acquired			$ 271
Pharma Segment | Vivus
Goodwill and Intangible Assets [Line Items]
Number of approved therapies | item			2
Number of product candidate in active clinical development | item			1
Automotive parts [Member]
Goodwill and Intangible Assets [Line Items]
Goodwill, Change in Goodwill Allocation, Description		27.00%
Developed Technology
Goodwill and Intangible Assets [Line Items]
Business combination, definite-lived intangible assets acquired			$ 250
Net Carrying Value			$ 248
Developed Technology | Pharma Segment | Vivus
Goodwill and Intangible Assets [Line Items]
Number of approved therapies | item			2
Developed Technology | Pharma Segment | Minimum | Vivus
Goodwill and Intangible Assets [Line Items]
Useful life			5 years
Developed Technology | Pharma Segment | Maximum | Vivus
Goodwill and Intangible Assets [Line Items]
Useful life			18 years
In Process Research and Development [Member]
Goodwill and Intangible Assets [Line Items]
Business combination, definite-lived intangible assets acquired			$ 21